Angelalign Technology Inc. (HKG:6699)
Hong Kong · Delayed Price · Currency is HKD 67.50
+1.45 (2.20%)
Aug 15, 2025, 4:08 PM HKT
Angelalign Technology Revenue
In the year 2024, Angelalign Technology had annual revenue of $268.79M USD with 28.23% growth. Angelalign Technology had revenue of $75.38M in the quarter ending December 31, 2024, with 22.87% growth.
Revenue
$268.79M
Revenue Growth
+28.23%
P/S Ratio
5.52
Revenue / Employee
$75.16K
Employees
3,576
Market Cap
11.53B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 268.79M | 59.17M | 28.23% |
| Dec 31, 2023 | 209.62M | 25.53M | 13.87% |
| Dec 31, 2022 | 184.09M | -16.09M | -8.04% |
| Dec 31, 2021 | 200.18M | 75.11M | 60.06% |
| Dec 31, 2020 | 125.07M | 32.31M | 34.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 35.81B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 71.34B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Sino Biopharmaceutical | 30.72B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |